Showing results (531-540 of 631) with videos related to
Sort By:
Pageof 64
The British Journal of Surgery|November 5, 2003
Plasminogen mediates liver regeneration and angiogenesis after experimental partial hepatectomyT A Drixler, J M Vogten, M F B G Gebbink, et al.Cancer Research|April 6, 2001
Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-AA Kadambi, C Mouta Carreira, C O Yun, et al.Thrombosis and Haemostasis|May 11, 1999
Structural and functional basis of plasminogen activation by staphylokinaseL Jespers, S Vanwetswinkel, H R Lijnen, et al.Thrombosis and Haemostasis|August 3, 1992
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinaseM Dewerchin, A M Vandamme, P Holvoet, et al.Thrombosis and Haemostasis|August 30, 1985
Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisolM F Aillaud, I Juhan-Vague, M C Alessi, et al.Coronary Artery Disease|March 1, 1995
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogsL Jun, J Arnout, P Vanhove, et al.Journal of the American College of Cardiology|July 1, 1986
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasisW Flameng, J Vanhaecke, D C Stump, et al.The Journal of Biological Chemistry|October 25, 1990
Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectinK T Preissner, J Grulich-Henn, H J Ehrlich, et al.Circulation|February 1, 1989
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosisA A Ziskind, H K Gold, T Yasuda, et al.Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|December 1, 1993
A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboonsC Kohmura, H K Gold, T Yasuda, et al.Pageof 64